

Transforming the fight against cancer

NanOlogy™ has transformed systemic chemotherapy into local delivery directly to the site of disease to improve the lives of patients with cancer.

HIGHLIGHTS

Innovative approach

Patented technology transforms paclitaxel and docetaxel into submicron particle NanoPac® and NanoDoce® for direct delivery to disease site.

Extensive pipeline

Six Phase 2 trials ongoing in ovarian, prostate and pancreatic cancers, cutaneous metastases, pancreatic cysts and actinic keratosis.

Partnering opportunities

Seeking partners to advance development through pivotal trials, regulatory approval, and to market.

OVERVIEW


NanOlogy, LLC is a clinical stage pharmaceutical development company formed by the collaboration of DFB Pharmaceuticals, CritiTech, and US Biotest to advance our patented submicron particle production technology platform for the treatment of cancer and other serious illnesses.

Starting with the world's most prescribed systemic chemotherapy agents, our technology platform reduces unprocessed paclitaxel and docetaxel API crystals by up to 400 times into patented, stable, naked submicron particles with tremendous surface area and unique geometry.

NanOlogy has developed these submicron particles into sterile suspension, topical, and inhalable product forms and has extensive clinical and preclinical programs underway to evaluate these investigational products across multiple indications in cancer and related illnesses.



STRONG VALUE PROPOSITION



Streamlined Path to Regulatory Approval

Six Phase 2 Clinical Trials Underway

Clinical Results in 2018

Preclinical Data in Lung, Prostate, Breast, Ovarian, and Bladder Cancers

Potential synergy with other therapies

Extensive Intellectual Property Portfolio including composition patent on the particles

Indications under evaluation total more than \$13 Billion in annual US treatment costs

PROMISING PRECLINICAL/CLINICAL DATA

STERILE SUSPENSION FOR INSTILLATION

- Ovarian tumor eradication in preclinical studies
- 5 of 21 salvage patients survived > 400 days in phase 1 ovarian trial
- Clearance from peritoneum > 4 weeks at subtoxic levels
- No drug related adverse events or bowel obstruction in phase 1 ovarian trial

TOPICAL

- Evidence of AK lesion reduction in phase 2 trial
- No local irritation and negligible systemic absorption following topical application over 28 days

STERILE SUSPENSION FOR DIRECT INJECTION

- Sustained tumor reduction or eradication across multiple tumor types in preclinical studies
- Gradual clearance from injection site at low levels in preclinical studies
- No serious adverse events to date in phase 2 clinical trials

NEBULIZED INHALATION

- Preclinical pharmacology study has been completed in NSCLC
- Drug retained in lung tissue > 14 days and no gross or histological abnormalities in lung tissue observed in preclinical PK studies

ACCELERATED DEVELOPMENT PIPELINE

Investigational products in nonclinical or clinical development

Product	Delivery	Sponsor	Indication	Preclinical	Phase 1	Phase 2	Phase 3
NanoPac® for Suspension <i>Sterile Nanoparticle Paclitaxel</i>	Intraperitoneal Instillation	NanOlogy	Ovarian Cancer	→	→	→	
	Intratumoral	NanOlogy	Prostate Cancer	→	→	→	
	Intratumoral	NanOlogy	Pancreatic Cancer	→	→	→	
	Intracystic	NanOlogy	Pancreatic Cyst	→	→	→	
NanoPac® for Nebulized Inhalation <i>Nanoparticle Paclitaxel</i>	Lung Inhalation	NanOlogy	Non Small Cell Lung Cancer	→			
NanoDoce® for Suspension <i>Sterile Nanoparticle Docetaxel</i>	Local	NanOlogy	Bladder Cancer	→			
NanoPac® Ointment (SOR007) <i>Nanoparticle Paclitaxel Ointment</i>	Topical	NanOlogy	Cutaneous Metastases	→	→	→	
	Topical	Soria	Actinic Keratosis	→	→	→	⊗ NanOlogy

THE NANOLOGY MANAGEMENT TEAM

H. Paul Dorman, Chairman & CEO, DFB Pharmaceuticals

Gere diZerega, MD, CEO, US Biotest

Mark Mitchell, Chief Legal Officer & Managing Director, DFB Pharmaceuticals

Maxwell Lea, Managing Director, DFB Pharmaceuticals

Marc Iacobucci, Managing Director, DFB Pharmaceuticals

Sam Campbell, Chairman, Critech

Matthew McClorey, President, Critech

Michael Baltezor, PhD, Chief Scientific Officer, Critech

NANOLOGY ADVISORS

Maurie Markman, MD, MS, FACP, FASCO, President, Medicine & Science, Cancer Treatment Centers of America®



Marc Iacobucci - marc.iacobucci@dfb.com; +817-916-2247
Maxwell Lea - maxwell.lea@dfb.com; +817-900-4084
www.nanology.us